隐丹参酮|cas:35825-57-1|西域试剂

隐丹参酮,分析标准品,HPLC≥98.7%

产品编号：西域质检-TM24726| CAS NO：35825-57-1| 分子式：C₁₉H₂₀O₃| 分子量：296.360

药理药效：具有抗氧化、抗衰老功能，对治疗冠心病、心绞痛、心肌损害有一定疗效。隐丹参酮具有抑菌作用，1mg/ml对金黄色葡萄球菌及绿脓杆菌均有抑制作用，对溶血性链球菌亦有一定抑制作用。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
西域质检-TM24726		￥600.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

隐丹参酮

Reference Material

This certificate is designed in accordance with ISO 17034 and ISO Guide 31. This reference material (RM) was designed,produced and verified in accordance with ISO/IEC 17025, ISO 17034 and a registered quality management system ISO 9001.

Product Name(产品名称) Cryptotanshinone(隐丹参酮)

Product Code(产品编号) 716772-50mg

Lot Number(产品批号) 22110927

CAS No. 35825-57-1

Mol. Weight(分子量) 296.36

Mol. Formula(分子式) C₁₉H₂₀O₃

Melting Point(熔点) N/A

Expiry Date(失效日期) 2024-Nov-29

Boiling point(沸点) N/A

Appearance(外观) Orange Solid
(橙色固体)_____

Storage Temp(存储条件) (2~8)℃,dark
冷藏(2~8)℃避光

C E R T I F I E D

Purity

98.7%

C E R T I F I E D

Expanded Uncertainty (U)

0.8%

Uncertainty

The certified value(s) and uncertainty(ies) are determined in accordance with ISO 17034 with an 95% confidence level(k=2). Uncertainty is based on the Total Combined Uncertainty, including uncertainties of characterisation, homogeneity and stability testing. Stability values are based on real evidence opposed to simulation.

Traceability

The balances used for gravimetric measurements are calibrated with weights traceable to the national standards. The calibration of the balances is verified annually by an external accredited calibration service. This analysis method has been verified using an approach consistent with ISO 17034:2016 & ISO 17025:2017.

CERTIFICATE ON	QC SIGNATURE
2022-Nov-30		RM Release

Method of Identification

HPLC

Method of Identification

HPLC

Intended Use

This RM is intended for use in a laboratory as a calibration and quality control standard or in method development for analytical techniques.

Storage

This reference material meets the specification stated in this certificate until the expiry date, provided it is stored unopened at the recommended temperature here in. If storage after opening is necessary, the RM should be tightly closed and kept from light and moisture.

Hazards

Read Material Safety Data Sheet (MSDS) and understand any potential hazard(s) prior to the use of this product. All chemicals should be considered potentially hazardous in nature and should only be handled by qualified personnel using established good laboratory practices.

Homogeneity

Random replicate samples of the final packaged RM have been analysed to prove homogeneity compliant with ISO 17034.

Instructions for use

It is recommended to use 1 mg as the minimum sample size and if less material is used, to increase the certified uncertainty by a factor of two for half sample and four for a quarter of sample.Visit the support section of our website technology videos and frequently asked questions.

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

符号	GHS06, GHS09
信号词	Danger
危害声明	H301-H410
警示性声明	P273-P301 + P310-P501
个人防护装备	dust mask type N95 (US);Eyeshields;Gloves
危害码 (欧洲)	T,N
风险声明 (欧洲)	25-50/53
安全声明 (欧洲)	45-60-61
危险品运输编码	UN2811 - class 6.1 - PG 3 - EHS - Toxic solids, organic, n.o.s., HI: all
RTECS号	SF8282645
海关编码	2932999099

1. 物质的识别

产品名：	Cryptotanshinone
CAS号：	35825-57-1
制造商/供应商：	西域试剂网站：www.hzbp.cn 邮件：13911702513@139.com

2. 合成/成分数据

产品名：	Cryptotanshinone
别名：	CTS
分子式：	C19H20O3
分子量：	296.36

3. 急救措施

吸入后：	如果吸入，移至空气新鲜处，如果呼吸困难，给输氧，如呼吸停止，给予人工呼吸。
皮肤接触后：	用大量的水冲洗，移除污染的衣服和鞋子。
眼睛接触后：	检查并取下隐形眼镜，并用大量的水冲洗；呼叫医生。
吞食后：	如果吞食，用大量纯净水漱口；呼叫医生。

4. 消防措施

适当的灭火剂：	雾状水，二氧化碳，干粉或泡沫。
防护设备：	穿戴自给式呼吸器和防护服，以防止与皮肤和眼睛接触。

5. 泄漏应急处理

安全防范措施：	封锁泄漏区域；穿戴自给式呼吸器，防护服和厚橡胶手套。
清洁/收集措施：	使用液体粘合原料（硅藻土，通用粘合剂）吸取精细粉末；使用酒精擦洗表面和设备除去污渍；根据第11条处理被污染的材料。

6. 处理和储存

安全处理说明：	避免吸入和接触皮肤，眼睛及衣物；材料可能略微具有刺激性。
储存：	粉末型式 -20°C 3年；4°C 2年溶于溶剂 -80°C 6个月；-20°C 1个月

7. 接触控制和个人防护

呼吸设备：	NIOSH / MSHA认可的呼吸器。
双手保护：	耐化学腐蚀的橡胶手套。
眼睛防护：	化学安全护目镜。

8. 稳定性和反应活性

稳定性：	按照说明存储是稳定的；避免强氧化剂。
热分解/其他要避免的情况：	避免光和热。

9. 毒性资料

急性毒性：	无可用资料。
主要刺激性影响：	无可用资料。
在皮肤上：	无可用资料。
对眼睛：	无可用资料；可能具有刺激性。

10. 生态资料

一般注意事项：

无可用资料。

11. 废弃处置

按照所在国家，省份，县市和地方的法规处置。

12. 运输信息

正确的运输名称：	无
非危险品运输：	这种物质被视为非危险品运输。

13. 法规信息

尚未有针对此产品作出的化学安全性评估。

14. 其他信息

上游产品 9
109664-02-0 2270-59-9 578-57-4 171979-69-4
33214-70-9 100-66-3 171979-70-7 171979-68-3
171979-67-2
下游产品 2
109664-02-0 568-72-9

43. [6.449] Chaogeng Lyu et al."A field trials-based study reveals the effects of chlormequat chloride on the quality of medicinal plant Salvia miltiorrhiza Bge. (Lamiaceae) in practical cultivation."INDUSTRIAL CROPS AND PRODUCTS.2023 Apr;194:116396

42. [6.208] Huan Zhao et al."Dihydrotanshinone I Inhibits the Lung Metastasis of Breast Cancer by Suppressing Neutrophil Extracellular Traps Formation."INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.2022 Jan;23(23):15180

41. [IF=1.496] Wenkai Wu et al."Cryptotanshinone From Salvia miltiorrhiza Inhibits the Growth of Tumors and Enhances the Efficacy of Chemotherapy in a Gastric Cancer Mouse Model."Natural Product Communications

40. [IF=5.988] Keke Guo et al."Cryptotanshinone protects skin cells from ultraviolet radiation-induced photoaging via its antioxidant effect and by reducing mitochondrial dysfunction and inhibiting apoptosis."Frontiers in Pharmacology.2022; 13: 1036013

39. [IF=0] Danni Wang et al."Identification of Q-Markers from Hedan Tablet by employing “spider-web” mode and taking compounds’ hepatotoxicity into account."Chinese Herbal Medicines.2022 Aug;:

38. [IF=6.317] Ping Huang et al."Optimization of smashing tissue and ultrasonic extraction of tanshinones and their neuroprotective effect on cerebral ischemia/reperfusion injury by inhibiting parthanatos."Food & Function.2022 Aug;:

37. [IF=6.627] Jiadong Hu et al."Identification of Abietane-Type Diterpenoids and Phenolic Acids Biosynthesis Genes in Salvia apiana Jepson Through Full-Length Transcriptomic and Metabolomic Profiling."Frontiers in Plant Science.2022; 13: 919025

36. [IF=7.376] Chengtao Sun et al."Dihydrotanshinone I inhibits ovarian tumor growth by activating oxidative stress through Keap1-mediated Nrf2 ubiquitination degradation."Free Radical Bio Med. 2022 Feb;180:220

35. [IF=6.057] Qi Tong et al.Biosynthesis-based spatial metabolome of Salvia miltiorrhiza Bunge by combining metabolomics approaches with mass spectrometry-imaging.Talanta. 2021 Nov;:123045

34. [IF=2.971] Rubin Cheng et al."Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia."Pharm Biol. 2021;59(1):893-903

33. [IF=3] Qu Lala et al."Phenotypic assessment and ligand screening of ETA/ETB receptors with label-free dynamic mass redistribution assay."N-S Arch Pharmacol. 2020 Jun;393(6):937-950

32. [IF=3.411] Liu Hongyan et al."Effect Study of Continuous Monoculture on the Quality of Salvia miltiorrhiza Bge Roots."Biomed Res Int. 2020;2020:4284385

31. [IF=3.51] Li-Ying Peng et al."Salvia miltiorrhiza Restrains Reactive Oxygen Species-Associated Pulmonary Fibrosis via Targeting Nrf2-Nox4 Redox Balance."Am J Chinese Med. 2019 Aug;47(05):1113-1131

30. [IF=3.69] Qian Zhang et al."Qishen Granule alleviates endoplasmic reticulum stress-induced myocardial apoptosis through IRE-1-CRYAB pathway in myocardial ischemia."J Ethnopharmacol. 2020 Apr;252:112573

29. [IF=4.411] Xiaoping Wang et al."Cryptotanshinone Ameliorates Doxorubicin-Induced Cardiotoxicity by Targeting Akt-GSK-3β-mPTP Pathway In Vitro."Molecules. 2021 Jan;26(5):1460

28. [IF=4.411] Yuanyuan Li et al."Quantitative Determination and Validation of Four Ketones in Salvia miltiorrhiza Bunge Using Quantitative Proton Nuclear Magnetic Resonance Spectroscopy."Molecules. 2020 Jan;25(9):2043

27. [IF=5.34] Tao-Fang Cheng et al."Compound Dan Zhi tablet attenuates experimental ischemic stroke via inhibiting platelet activation and thrombus formation."Phytomedicine. 2020 Dec;79:153330

26. [IF=6.475] Shi Qiu et al."Selection of appropriate post-harvest processing methods based on the metabolomics analysis of Salvia miltiorrhiza Bunge."Food Res Int. 2021 Jun;144:110366

25. [IF=7.514] Tong Wang et al."A hydrophobic deep eutectic solvents-based integrated method for efficient and green extraction and recovery of natural products from Rosmarinus officinalis leaves, Ginkgo biloba leaves and Salvia miltiorrhiza roots."Food Chem. 2021 Nov;3

24. [IF=3.361] Taofang Cheng et al."Hybrid multidimensional data acquisition and data processing strategy for comprehensive characterization of known, unknown and isomeric compounds from the compound Dan Zhi Tablet by UPLC-TWIMS-QTOFMS."Rsc Adv. 2019 Mar;9(16):8714-8727

23. [IF=3.414] Yu-xiang Fei et al."Salvia miltiorrhiza Bunge (Danshen) extract attenuates permanent cerebral ischemia through inhibiting platelet activation in rats."J Ethnopharmacol. 2017 Jul;207:57

22. [IF=3.935] Nan Mi et al."Metabolite profiling of traditional Chinese medicine formula Dan Zhi Tablet: An integrated strategy based on UPLC-QTOF/MS combined with multivariate statistical analysis."J Pharmaceut Biomed. 2019 Feb;164:70

21. [IF=5.64] Wu Dousheng et al."Oleanolic Acid Induces the Type III Secretion System of Ralstonia solanacearum."Front Microbiol. 2015 Dec;0:1466

20. [IF=7.514] Tiehua Zhang et al."In vitro and in silico perspectives on estrogenicity of tanshinones from Salvia miltiorrhiza."Food Chem. 2019 Jan;270:281

19. Xia, Yanqiu, et al. "Cryptotanshinone reverses reproductive disturbances in rats with dehydroepiandrosterone-induced polycystic ovary syndrome." American journal of translational research 9.5 (2017): 2447.

18. 李晓婷,决利利,郝海军,王世广.隐丹参酮纳米混悬剂的制备及其抗肿瘤活性[J].中成药,2021,43(01):6-10.

17. 马丽娟,王锡恩,刘培,陈蜜,张静,彭敏.隐丹参酮调控Wnt/β-catenin信号通路对胃癌细胞抑制作用的研究[J].新中医,2020,52(21):1-5.

16. 陈天朝,耿梦丽,马彦江,李沁,姚超,程思卿,王娇.丹参不同炮制品饮片与标准汤剂的物性参数及化学成分相关性[J].中成药,2021,43(03):824-829

15. 赵志国, 段文娟, 张晓梦,等. HPLC-DAD-ESI-TOF/MS鉴别和测定前列欣胶囊中多种成分及其多指标定量指纹图谱研究[J]. 药物分析杂志, 2017, 037(010):1810-1816.

14. 李清清张继芬. 冠心宁中14种成分的含量测定[J]. 苏盐科技 2019 046(006):33-35.

13. 王芸, 陈军峰, 张磊,等. 基于"有效成分-性状"的关联分析评价丹参品质的研究[J]. 世界科学技术:中医药现代化, 2019(5):835-843.

12. 崔伟亮. 丹参酒炙前后HPLC指纹图谱色谱峰归属比较[J]. 辽宁中医杂志, v.46;No.507(08):1707-1709.

11. 敏敏赵志国刘伟等. HPLC-DAD法同时测定三种来源丹参饮片中水溶性和脂溶性成分[J]. 山东科学 2019(6).

10. 石蔚华赵筱萍陈晓玲.三叶糖脂清DPP-4抑制成分筛选及其调控JNK/AKT信号通路改善胰岛素抵抗的机制研究[J].浙江中医药大学学报 2019 43(01):7-13.

9. 闫妍石磊史宁郭宏举耿帅温彬宇.UPLC-Q-TOF-MS同时测定天王补心片中丹参的主要成分[J].解放军药学学报 2018 34(01):55-57.

8. 孙锦林力彭勍等. 不同浓度乙醇提取丹参中12种成分比较研究[J]. 中国中医药信息杂志 2019(9).

7. 郝海军, 屈战果, 范明松. 隐丹参酮纳米结构脂质载体的制备及药动学研究[J]. 中成药, 2020, 042(004):831-835.

6. 邓凤春, 于占江, 杨钰,等. 隐丹参酮对人胃癌细胞SGC-7901凋亡的影响及其机制[J]. 北京中医药大学学报, 2015.

5. 邓凤春, 杨钰, 赵红晔,等. 隐丹参酮抑制人胃癌SGC-7901细胞增殖的实验研究[J]. 中外医疗, 2014(35):49-50.

4. 彭国文,柳超,時晓静,郝海军.隐丹参酮固体脂质纳米粒的制备及药动学研究[J].中药材,2019,42(03):626-629.

3. 何家杰,李敏,唐国富,李厚泽,綦晓龙.异隐丹参酮对胃癌细胞增殖、周期和凋亡的影响[J].临床肿瘤学杂志,2019,24(02):129-132.

2. 张玉, 戚莹雪, 王蕾,等. 山东丹参脂溶性成分的地域分布特点研究[J]. 中药材, 2018, 041(011):2522-2526.

1. 张芮乾,吴晓毅,胡添源,宋雅迪,高伟,黄璐琦.基于丹参酮类化合物生源途径的丹参质量标志物研究思路探讨[J].中国中药杂志,2020,45(13):3098-3103.